Seribantumab
Seribantumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 4 | 1 | — | — | — | 5 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | — | — | — | 5 |
| Non-small-cell lung carcinoma | D002289 | 3 | 2 | — | — | — | 4 | ||
| Colorectal neoplasms | D015179 | 2 | 1 | — | — | — | 3 | ||
| Triple negative breast neoplasms | D064726 | 1 | 1 | — | — | — | 2 | ||
| Fallopian tube neoplasms | D005185 | 1 | 1 | — | — | — | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 2 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | 1 | — | — | — | 1 | ||
| Ovarian epithelial carcinoma | D000077216 | — | 1 | — | — | — | 1 | ||
| Peritoneal neoplasms | D010534 | — | 1 | — | — | — | 1 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma of head and neck | D000077195 | 2 | — | — | — | — | 2 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SERIBANTUMAB |
| INN | seribantumab |
| Description | Seribantumab (INN; development code MM-121) is a monoclonal antibody designed for the treatment of cancer.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1334296-12-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545071 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11857 |
| UNII ID | 1N3L70MDFX (ChemIDplus, GSRS) |
Target
Agency Approved
ERBB3
ERBB3
Organism
Homo sapiens
Gene name
ERBB3
Gene synonyms
HER3
NCBI Gene ID
Protein name
receptor tyrosine-protein kinase erbB-3
Protein synonyms
human epidermal growth factor receptor 3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
Uniprot ID
Mouse ortholog
Erbb3 (13867)
receptor tyrosine-protein kinase erbB-3 (Q8K317)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 154 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more